Novel Oral Anticoagulants in Cardiovascular Practice

Authors

  • Syed Haseeb Raza Chaudhry Pervaiz Elahi Institute of Cardiology, Multan, Pakistan
  • Han Naung Tun University of Vermont, Burlington City, Vermont State, USA
  • F. Aaysha Cader Ibrahim Cardiac Hospital & Research Institute, Dhaka, Bangladesh
  • Jolanda Sabatino University of Padua, Italy
  • Madiha Fatima National Institute of Cardiovascular Diseases, Karachi, Pakistan

DOI:

https://doi.org/10.47144/phj.v56i4.2618

Abstract

In the recent era of medicine, Novel Oral Anticoagulants (Apixaban, Dabigatran, Edoxaban, and Rivaroxaban) have become the preferred drugs for long-term anticoagulation therapy in the majority of cardiovascular conditions, along with non-cardiac co-morbid conditions with few necessary exceptions. This preference is based on their easy availability, therapeutic efficacy, all-cost effectiveness, safety profile, and more convenient usage for both patients and clinicians.

Novel Oral Anticoagulants (NOACs) have different pharmacokinetics and pharmacodynamics than oral vitamin K antagonists. This article highlights the basic pharmacology, common complications, available antidotes, and the utility of NOACs in different common cardiovascular diseases requiring long-term oral anticoagulation, including stroke prevention in valvular and non-valvular atrial fibrillation, coronary artery disease, myocardial infarction, left ventricular thrombus and cerebrovascular attacks.

NOACs are still underutilized in cardiovascular practice because the concomitant co-morbid conditions hinder a clinician from prescribing these drugs confidently. This manuscript will provide a brief critical overview to help clinicians prescribe NOACs more conveniently.

Downloads

Download data is not yet available.

Downloads

Published

2023-12-31

How to Cite

1.
Raza SH, Tun HN, Cader FA, Sabatino J, Fatima M. Novel Oral Anticoagulants in Cardiovascular Practice. Pak Heart J [Internet]. 2023Dec.31 [cited 2024Mar.3];56(4):250-5. Available from: https://pakheartjournal.com/index.php/pk/article/view/2618